The reduction in price target by Piper Sandler from $12 to $5, while maintaining an Overweight rating, suggests a reassessment of Aptose Biosciences' valuation or growth prospects. This significant decrease in the price target could lead to short-term negative sentiment among investors, potentially impacting the stock price negatively.